Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
Maha Abdalla, PharmD, PhD, RPh
Advertisement
Articles by Maha Abdalla, PharmD, PhD, RPh
New trials explore glucagon-like peptide-1 receptor agonists for alcohol, nicotine use disorder, and smoking cessation.
Advertisement
Latest Updated Articles
GLP-1s: A New Frontier in Substance Use Disorder ManagementAugust 10th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Pneumococcal Vaccines Show Moderate Immunogenicity, Strong Safety in Children With Cancer
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5